Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Enterprise Value (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Enterprise Value for 11 consecutive years, with -$213.2 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value changed N/A to -$213.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$213.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$213.2 million for FY2025, N/A changed from the prior year.
  • Enterprise Value for Q4 2025 was -$213.2 million at Crescent Biopharma, down from -$133.3 million in the prior quarter.
  • The five-year high for Enterprise Value was -$5.6 million in Q1 2025, with the low at -$213.2 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$73.0 million, with a median of -$59.1 million recorded in 2022.
  • Peak annual rise in Enterprise Value hit 82.06% in 2025, while the deepest fall reached 825.99% in 2025.
  • Over 5 years, Enterprise Value stood at -$90.3 million in 2021, then soared by 46.96% to -$47.9 million in 2022, then grew by 12.7% to -$41.8 million in 2023, then surged by 65.56% to -$14.4 million in 2024, then plummeted by 1381.41% to -$213.2 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$213.2 million, -$133.3 million, and -$5.6 million for Q4 2025, Q3 2025, and Q1 2025 respectively.